Lynne Chou O'Keefe

Founder & Managing Partner
Define Ventures

Ms. Lynne Chou O'Keefe serves as a Partner at Kleiner Perkins Caufield & Byers. Ms. O'Keefe joined Kleiner Perkins in 2013 and focuses on digital health and connected devices. She served as Partner of Life Sciences Group at the firm. Ms. O'Keefe spent eight years in various roles at Abbott Vascular, where she worked on the launch of over ten interventional cardiology and cardiac surgery products in the United States and internationally. She was also at Guidant in multiple roles. She led the global launch of Absorb and was responsible for building the global commercial strategy and therapy development as well as playing a key role in the clinical, reimbursement, operational strategy for the therapy. She was an Associate at Apax Partners LLP, focusing on software venture capital investing. She joined the Apax Partners in 2001. Ms. O'Keefe served as a Financial Analyst in the Merger and Acquisitions Group at Goldman, Sachs & Co. and focused on providing strategic advisory services to corporations in a wide range of industries, including technology, retail, food, and industrials and worked on multiple multi-billion dollar acquisitions and sell side transactions in various industries. Currently, she serves on the Board of Directors of Hixme, Kinsa, Lumeris, Mango Health, and Zephyr Health. She serves as a Board Observer at Livongo Health, Inc. She has been a Director of California Health Care Foundation Inc. since 2018. She has over 12 years of healthcare operating and investing experience. She works alongside entrepreneurs to develop impact full technologies and therapies. Ms. O'Keefe holds an M.B.A. from Harvard Business School during 2003 to 2005, and graduated with a Bachelor of Science degree in Industrial Engineering from Stanford University during 1995 to 1999.

Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.

Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.